P
Patricia Pautier
Researcher at Institut Gustave Roussy
Publications - 451
Citations - 13277
Patricia Pautier is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Ovarian cancer. The author has an hindex of 53, co-authored 391 publications receiving 10203 citations. Previous affiliations of Patricia Pautier include Université Paris-Saclay & Curie Institute.
Papers
More filters
Journal ArticleDOI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine,Jonathan A. Ledermann,Frédéric Selle,Val Gebski,Richard T Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo,Philipp Harter,Keiichi Fujiwara,Isabelle Ray-Coquard,Susana Banerjee,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Patricia Pautier,Tomasz Byrski,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Andrés Poveda Velasco,Manuel Rodrigues,Jean-Pierre Lotz,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Medioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie-Christine Kaminsky,Béatrice Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Jonathan Cosin,James Hoffman,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,H. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae Hoon Kim,Jae Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O'Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,Maria Pilar Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez de Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid A. Boere,Petronella B. Ottevanger,Joo-Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan E Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado Herraez,César Mendiola Fernández,Martina Gropp-Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung-Gie Kim,Jae Weon Kim,Jae Weon Kim,Roberto Hegg,Ignace Vergote +110 more
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard,Patricia Pautier,Sandro Pignata,David Pérol,Antonio González-Martín,Regina Berger,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,J. Maenpaa,Frédéric Selle,Jalid Sehouli,Domenica Lorusso,Eva Guerra Alia,Alexander Reinthaller,Shoji Nagao,C. Lefeuvre-Plesse,Ulrich Canzler,Giovanni Scambia,Alain Lortholary,Frederik Marmé,Pierre Combe,Nikolaus de Gregorio,Manuel Rodrigues,Paul Buderath,Coraline Dubot,Alexander Burges,Benoit You,Eric Pujade-Lauraine,Philipp Harter +29 more
TL;DR: In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.
Journal ArticleDOI
Malignant effusions and immunogenic tumour-derived exosomes
Fabrice Andre,Noël E. C. Schartz,Mojgan Movassagh,Caroline Flament,Patricia Pautier,Philippe Morice,Christophe Pomel,Catherine Lhommé,Bernard Escudier,Thierry Le Chevalier,Thomas Tursz,Sebastian Amigorena,Graça Raposo,Eric Angevin,Laurence Zitvogel +14 more
TL;DR: Exosomes from patients with melanoma deliver Mart1 tumour antigens to dendritic cells derived from monocytes for cross presentation to clones of cytotoxic T lymphocytes specific to Mart1, opening up new avenues for immunisation against cancers.
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu,Susana Banerjee,P. Blecharz,Ilan Bruchim,David Cibula,Nicole Concin,Ben Davidson,Mojgan Devouassoux-Shisheboran,Annamaria Ferrero,R.M. Glasspool,Antonio González-Martín,Viola Heinzelmann-Schwarz,Florence Joly,J. W. Kim,Frédéric Kridelka,Domenica Lorusso,Sven Mahner,Mikio Mikami,Mansoor Raza Mirza,Shibani Nicum,Dearbhaile M. O'Donnell,Patricia Pautier,Alexandros Rodolakis,Jalid Sehouli,Fatih Selcukbiricik,Naveena Singh,David S.P. Tan,Dirk Timmerman,Germana Tognon,J. van der Velden,Petronella O. Witteveen,AG Zeimet +46 more
TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.
Journal ArticleDOI
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Caroline Robert,Jean-Charles Soria,Alain Spatz,Axel Le Cesne,David Malka,Patricia Pautier,Janine Wechsler,Catherine Lhommé,Bernard Escudier,Valérie Boige,Jean-Pierre Armand,Thierry Le Chevalier +11 more
TL;DR: The cutaneous side-effects seen after treatment with the inhibitors of epidermal-growth-factor receptor (EGFR), imatinib, sorafenib, and sunitinib are discussed, which could lead to the identification of crucial predictive factors for tumour response.